Pre-emptive Analgesics in Orthodontic Treatment
Launched by UNIVERSITY OF WASHINGTON · May 1, 2018
Trial Information
Current as of August 21, 2025
Completed
Keywords
ClinConnect Summary
This study is designed to determine if the preemptive use of a combination of acetaminophen and ibuprofen is more effective in reducing pain following orthodontic tooth movement when compared to the use of acetaminophen and ibuprofen alone. Before their orthodontic appointment, participants will be administered acetaminophen (650mg), ibuprofen (400mg), or acetaminophen (650mg) + ibuprofen (400mg). Participants will be asked to record their pain intensity using a numerical (0-10) visual analog scale (VAS) during rest, light biting, and while chewing paraffin wax during the following time int...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Orthodontic patient presenting for orthodontic treatment
- Exclusion Criteria:
- • History of taking an analgesic in the past six hours
- • Hypersensitivity to ibuprofen or acetaminophen
- • Aspirin-sensitive asthma
- • Renal or liver impairment
- • History of GI bleeding or ulcers
- • Cardiovascular disease, recent myocardial infarction, heart failure, or coronary artery bypass graft surgery
- • Currently taking antibiotics or other medications for a chronic systemic disease
- • Bleeding disorder
- • Pregnant or nursing
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Anne-Marie Bollen, DDS, MS, PhD
Study Director
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials